Opexa Therapeutics, Inc. (OPXA), a Woodlands, Texas-based biotechnology company, has officially reported its 2012 fiscal year financial results. Opexa is developing a novel T-cell therapy for MS (multiple sclerosis) known as Tcelna or Tovaxin and, despite loss reports for fiscal year 2011 and 2012, future finances are looking promising.
http://bionews-tx.com/news/2013/04/01/opexa-therapeutics-inc-reports-year-end-financial-results-not-reflective-of-companys-future/
No comments:
Post a Comment